Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
60.42
+1.67 (2.84%)
At close: Feb 6, 2026
168.77%
Market Cap37.34B +204.1%
Revenue (ttm)1.37B +12.0%
Net Income870.39M +139.3%
EPS1.39 +136.6%
Shares Out618.09M
PE Ratio43.42
Forward PE122.06
Dividend0.12 (0.21%)
Ex-Dividend DateNov 7, 2025
Volume7,008,779
Average Volume6,273,967
Open58.63
Previous Close58.75
Day's Range58.20 - 62.35
52-Week Range22.11 - 83.00
Beta0.94
RSI50.86
Earnings DateMar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,023
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.

Financial Statements